Third-course reirradiation provided symptom relief in selected patients with progressive DIPG
Across 12 reported patients receiving at least three radiation courses for DIPG, median survival was 27 months with frequent symptomatic benefit.
Tag
Reirradiation
Proton hypofractionation achieved durable control in heavily reirradiated spine metastases
Proton hypofractionation produced 10% one-year local failure despite extensive prior irradiation, with grade 3 toxicity confined to multiply reirradiated patients.
Structured cumulative-dose review triggered replanning in one-quarter of proton reirradiation cases
Voxel-wise cumulative EQD2 review prompted reoptimization in 25.5% of proton reirradiation courses and exposed frequent registration problems.
Minibeam radiotherapy achieved 92% one-year local control in refractory superficial tumors
In the first clinical minibeam series, 86% had symptomatic improvement and one-year local control reached 92% with minibeam treatment alone.
ESTRO review supports selective CNS reirradiation but highlights cumulative-dose limits
ESTRO supports individualized reirradiation for selected recurrent brain tumors, with cumulative dose, target volume and critical structures determining feasibility.
Deformable registration substantially changed cumulative dose estimates in stereotactic re-irradiation
DIR reduced estimated liver maximum dose from 123.8 to 83.2 Gy, but accuracy deteriorated markedly for bowel and stomach.
Re-irradiation was associated with longer survival after pediatric diffuse midline glioma progression
COMPPARE enrolled 2,524 patients from 51 institutions in 52 months, with Black participation reaching 16% of the cohort.
Iodine-125 brachytherapy achieved short-term control in previously irradiated cervical nodal metastases
Iodine-125 seed implantation produced 90% three-month disease control, but median local progression-free survival was nine months.
Five-fraction partial breast re-irradiation showed low toxicity after repeat lumpectomy
Twenty-five selected patients had 96% crude local control and no grade 3 toxicity after 26 Gy in five fractions.
ESTRO defines clinical standards for high-dose thoracic reirradiation in NSCLC
ESTRO recommends selective high-dose thoracic reirradiation with comprehensive staging, limited target volumes and formal cumulative dose assessment.
Pulsed photon reirradiation showed 27-month median progression-free survival in recurrent meningioma
Temporally modulated pulsed radiotherapy achieved a median progression-free survival of 27.2 months in large, previously irradiated recurrent meningiomas.
Prostate reirradiation strategies remain heterogeneous despite encouraging prospective outcomes
Prospective prostate reirradiation studies reported generally acceptable toxicity, but target volumes, dose schedules and organ constraints varied substantially.
Spine proton ablative radiotherapy achieved 74% two-year local control in selected patients
Spine proton ablative radiotherapy achieved 74% local control at one and two years, with no radiation myelopathy in a reirradiation-enriched cohort.
Carbon ion re-irradiation showed feasible salvage outcomes in recurrent pelvic sarcoma
High-dose carbon ion re-irradiation achieved 83.1% 3-year survival with no grade 4 toxicity in recurrent pelvic sarcoma.
Dutch survey found wide variation in radiotherapy for unresectable recurrent rectal cancer
Dutch radiation oncologists reported substantial variation in dose, delineation, and follow-up for unresectable locally recurrent rectal cancer.